Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in GBM and DIPG
NCT02758366Phase 2Terminated
- Sponsor
- Meyer Children's Hospital IRCCS
- Start
- Feb 2016
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin in glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), brainstem glioma, diffuse spinal glioma (DMG), thalamic glioma, sponsored by Meyer Children's Hospital IRCCS. Started Feb 2016; status: terminated.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)diffuse intrinsic pontine glioma (DIPG)brainstem gliomadiffuse spinal glioma (DMG)thalamic glioma
Beyond the preview
Go deeper on NCT02758366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758366.